DNDN's Provenge To Be First Approved Cancer Immunotherapy
Analysts at RW Baird initiate coverage of Dendreon (NASDAQ: DNDN) with an "outperform" rating. The target price for DNDN is set to $48.
According to RW Baird, Provenge is expected to be the first approved immunotherapy for cancer. RW Baird recommends buying Dendreon's shares into the high $40’s.
DNDN’s shares closed at $36.01 yesterday. More Analyst Ratings here
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
